Ian A. Cook
Technik-/Wissenschafts-/F&E-Leiter bei NeuroSigma, Inc.
Profil
Ian A.
Cook is currently the Director of the Transcranial Magnetic Stimulation Service at the Semel Institute for Neuroscience & Human Behavior, Chief Medical Officer & Senior Vice President at NeuroSigma, Inc., Professor at the David Geffen School of Medicine, and Professor at the Henry Samueli School of Engineering & Applied Science.
He received his undergraduate degree from Princeton University and his doctorate from Yale School of Medicine.
Aktive Positionen von Ian A. Cook
| Unternehmen | Position | Beginn |
|---|---|---|
NeuroSigma, Inc.
 NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2014 |
| Henry Samueli School of Engineering & Applied Science | Corporate Officer/Principal | 01.07.2013 |
| David Geffen School of Medicine | Corporate Officer/Principal | 01.07.2010 |
| Semel Institute For Neuroscience & Human Behavior | Corporate Officer/Principal | 01.01.2007 |
Ausbildung von Ian A. Cook
| Princeton University | Undergraduate Degree |
| Yale School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | Health Technology |
